HLB Pharmaceutical Co., Ltd. (KOSDAQ:047920)
South Korea
· Delayed Price · Currency is KRW 17,700
+10 (0.06%)
Apr 29, 2026, 3:30 PM KST
HLB Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 |
| Operating Revenue | 205,582 | 137,082 | 36,100 | 20,541 | 15,558 |
| Other Revenue | -0 | - | - | - | - |
| Revenue | 205,582 | 137,082 | 36,100 | 20,541 | 15,558 |
| Revenue Growth (YoY) | 49.97% | 279.73% | 75.75% | 32.03% | - |
| Cost of Revenue | 99,165 | 50,556 | 18,058 | 16,075 | 12,797 |
| Gross Profit | 106,416 | 86,526 | 18,042 | 4,465 | 2,760 |
| Selling, General & Admin | 99,402 | 80,198 | 13,672 | 7,281 | 3,417 |
| Research & Development | 3,337 | 2,451 | 1,870 | 2,474 | 2,736 |
| Amortization of Goodwill & Intangibles | 1,477 | 1,450 | 69.49 | 59.69 | 117.71 |
| Other Operating Expenses | 427.09 | 378.08 | 197.98 | 246.97 | 155.02 |
| Operating Expenses | 105,353 | 85,052 | 16,601 | 10,292 | 6,613 |
| Operating Income | 1,064 | 1,474 | 1,441 | -5,826 | -3,853 |
| Interest Expense | -738.08 | -621.14 | -1,192 | -859.58 | -2,107 |
| Interest & Investment Income | 654.91 | 429.94 | 36.96 | 392.45 | 531.35 |
| Earnings From Equity Investments | 2,324 | -1,121 | - | - | - |
| Currency Exchange Gain (Loss) | -0.54 | -3.96 | 1.79 | -5.17 | -76.26 |
| Other Non Operating Income (Expenses) | 1,394 | -3,184 | -90.42 | 447.16 | 828.7 |
| EBT Excluding Unusual Items | 4,699 | -3,026 | 196.89 | -5,851 | -4,676 |
| Gain (Loss) on Sale of Investments | 266.42 | - | 120.89 | 164.96 | -332.17 |
| Gain (Loss) on Sale of Assets | 53.12 | 16,406 | -2.08 | -31.53 | -45.09 |
| Asset Writedown | -32.67 | -12,215 | -438.73 | - | -509.63 |
| Pretax Income | 4,986 | 1,166 | -123.03 | -5,718 | -5,563 |
| Income Tax Expense | 414.02 | -854.13 | -595.69 | 1,342 | -116.36 |
| Net Income | 4,572 | 2,020 | 472.66 | -7,060 | -5,447 |
| Net Income to Common | 4,572 | 2,020 | 472.66 | -7,060 | -5,447 |
| Net Income Growth | 126.35% | 327.33% | - | - | - |
| Shares Outstanding (Basic) | 32 | 32 | 14 | 14 | 12 |
| Shares Outstanding (Diluted) | 33 | 32 | 14 | 14 | 12 |
| Shares Change (YoY) | 1.86% | 131.51% | 2.30% | 13.08% | - |
| EPS (Basic) | 141.00 | 64.00 | 34.13 | -521.49 | -455.00 |
| EPS (Diluted) | 140.00 | 63.00 | 34.13 | -521.49 | -455.00 |
| EPS Growth | 122.22% | 84.58% | - | - | - |
| Free Cash Flow | -6,642 | 4,042 | -43.8 | -2,872 | -3,020 |
| Free Cash Flow Per Share | -203.38 | 126.07 | -3.16 | -212.19 | -252.31 |
| Gross Margin | 51.76% | 63.12% | 49.98% | 21.74% | 17.74% |
| Operating Margin | 0.52% | 1.07% | 3.99% | -28.37% | -24.77% |
| Profit Margin | 2.22% | 1.47% | 1.31% | -34.37% | -35.01% |
| Free Cash Flow Margin | -3.23% | 2.95% | -0.12% | -13.98% | -19.41% |
| EBITDA | 5,176 | 6,563 | 3,081 | -4,684 | -2,798 |
| EBITDA Margin | 2.52% | 4.79% | 8.53% | -22.80% | -17.98% |
| D&A For EBITDA | 4,112 | 5,089 | 1,640 | 1,143 | 1,055 |
| EBIT | 1,064 | 1,474 | 1,441 | -5,826 | -3,853 |
| EBIT Margin | 0.52% | 1.07% | 3.99% | -28.36% | -24.77% |
| Effective Tax Rate | 8.30% | - | - | - | - |
| Advertising Expenses | 4,932 | 3,929 | 63.27 | 81.18 | 98.91 |
Source: S&P Capital IQ. Standard template. Financial Sources.